StemCells Inc announced that it has closed its previously announced offering of common stock and short term warrants. The Company sold a total of 11,299,435 units to two well recognized institutional biotechnology investors and received total proceeds, net of offering expenses and placement agent fees, of approximately $18.7 million.
Each unit consists of one share of common stock and a warrant to purchase 0.85 of a share of common stock at a price of $1.77 per unit. The warrants will first be exercisable six months from the date of issuance at an initial exercise price of $2.17 per share. The
Stem Cell Research Study Shows Adult Stem Cells Improve Diabetes Type 2
Dr. Roberto Fernandez Vina is scheduled to present a stem cell research study in which he helped improve Diabetes Type 2 patients with their own Adult Stem Cells and followed up on them for 3 years! The stem cell treatment and therapy was a […]
Emory University researchers are participating in a groundbreaking clinical trial to treat patients with amyotrophic lateral sclerosis (ALS) using human neural stem cells.
The Phase 1 trial, will assess the safety of stem cells, and the surgical procedures and devices required, for multiple injections of the cells directly into the spinal cord.
“This is the first U.S. clinical trial of stem cell injections into the spinal cord for the treatment of ALS,” says principal researcher Jonathan Glass, professor of neurology in the School of Medicin, and director of the Emory ALS Center. “Our main goal in this early phase is to
Image via Wikipedia
Stem cell therapy holds promise for the treatment of almost all human diseases, from spinal cord injuries to damage caused by heart attacks. Stem cells are the cells in our body that have the potential to “grow up” to be any type of cell in the body. But organs are more than just collections of cells. They’re highly organized collections of a multitude of cells.
All treatments with stems cells are still experimental, and therefore the risks of this treatment are not completely understood. Clinical trials are monitored in the United States by academic and government agencies to
John Lawson Cullison Jr., an artist lost his ability to paint due to the effects of arthritis. This incurable condition is due to the degeneration in cartilage tissue and symptoms include: pain, tenderness in the joints, stiffness, loss of flexibility, bone spurs and severe swelling. Pain management and joint replacement surgery are the typical means to treating this condition.
RNL BIO, a South Korean adult stem cell therapy company, developed a method to take one’s own stem cells from fat tissue and make identical copies that have no genetic modifications and no cancer risks so that high doses of stem